Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Expected to Rise, Citigroup Analyst Says

Syndax Pharmaceuticals (NASDAQ:SNDX) had its target price upped by Citigroup from $37.00 to $45.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on SNDX. StockNews.com upgraded shares of Syndax Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, November 15th. Barclays boosted their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the stock an “overweight” rating in a research report on Thursday, August 15th. Bank of America increased their price objective on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, August 15th. UBS Group started coverage on Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price on the stock. Finally, HC Wainwright increased their price target on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a “buy” rating in a research note on Monday. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.18.

Syndax Pharmaceuticals Trading Down 2.1 %

Shares of NASDAQ:SNDX opened at $15.77 on Tuesday. The firm’s 50 day moving average is $18.82 and its two-hundred day moving average is $20.15. The firm has a market capitalization of $1.35 billion, a P/E ratio of -4.34 and a beta of 0.92. Syndax Pharmaceuticals has a 52 week low of $14.97 and a 52 week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the business earned ($0.73) earnings per share. Analysts predict that Syndax Pharmaceuticals will post -3.61 EPS for the current year.

Institutional Investors Weigh In On Syndax Pharmaceuticals

Several large investors have recently modified their holdings of SNDX. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Syndax Pharmaceuticals during the second quarter valued at $27,000. Values First Advisors Inc. acquired a new stake in Syndax Pharmaceuticals during the 3rd quarter worth about $30,000. nVerses Capital LLC purchased a new stake in Syndax Pharmaceuticals during the second quarter valued at about $33,000. Quantbot Technologies LP acquired a new position in shares of Syndax Pharmaceuticals in the third quarter worth about $49,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock worth $58,000 after acquiring an additional 541 shares in the last quarter.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).